United States Patent 11,813,231 (Metoclopramide Intranasal): What Is Claimed and Where the Landscape Squeezes
US Patent 11,813,231 claims a specific metoclopramide intranasal formulation defined by pH, preservative selection and concentration, and a stability performance metric under accelerated storage. The enforceable scope is concentrated in claim 1, then narrowed by dependent claims that lock in device delivery, buffer selection, metoclopramide concentration, osmolality, and “substantially free” antioxidant language.
What is the core inventive scope in claim 1?
Claim 1: Intranasal metoclopramide composition defined by (i) formulation boundaries and (ii) a stability test result
Claim 1 requires an intranasal pharmaceutical composition with:
A. pH boundary
B. Active
- metoclopramide or a pharmaceutically acceptable salt
C. Preservative selection (mutually defined alternatives)
Either:
- benzalkonium chloride (BAC) at ≥ 0.025% (w/v) and up to about 0.05% (w/v)
OR
- benzyl alcohol at < 1% (w/v)
D. Stability requirement (performance metric)
- When stored at 40° C. and 75% relative humidity for at least about 4 weeks, the composition shows:
- < about 2% average change in percent optical density (O.D.) per week per 200 mg/mL of metoclopramide
Interpretation for scope
- The claim is not just a recipe. It has a measurable, formula-quality constraint tied to an accelerated stability readout (“percent optical density” change normalized to dose concentration and expressed per week).
- Even if a competitor matches pH and preservative bands, they still risk infringement if their product fails the <2%/week O.D.-change limitation.
How do dependent claims narrow or broaden infringement risk?
Preservative refinement and edge exposure
Dependent claims specify narrower BAC and benzyl alcohol bands:
-
Claim 16: BAC 0.025% to about 0.04% (w/v)
-
Claim 17: BAC 0.025% to about 0.03% (w/v)
-
Claim 18: BAC 0.025% (w/v)
-
Claim 9: benzyl alcohol up to about 0.8% (w/v)
-
Claim 19: benzyl alcohol about 0.01% to about 0.1% (w/v)
-
Claim 20: benzyl alcohol about 0.75% (w/v)
Scope effect
- Claim 1 covers BAC up to 0.05%; dependent claims carve out enforceable subranges and therefore sharpen claim charts at the margins.
- For BAC, the “practical infringement corridor” is likely to be easiest to argue at 0.025% to 0.03% because that range appears verbatim in dependent claims.
Active concentration and tonicity boundaries
- Claim 4: metoclopramide concentration 20.0% (w/v) to 30.0% (w/v)
- Claim 5: osmolality 500 mOsm/kg to 1400 mOsm/kg
Scope effect
- These limitations impose formulation constraints that are common in nasal sprays (but not universal). If a competitor uses a different concentration or targets a narrower osmolality window, they can reduce literal overlap with dependent claims (though claim 1 itself does not explicitly recite these parameters, so the independent claim can still be asserted unless a dependent claim is required in litigation).
Buffer selection is enumerated
- Claim 6: buffer selected from a long list (e.g., citric acid/phosphate, acetate, phosphate, many biologically used Good’s buffers, and others)
- Claim 7: buffer comprises sodium acetate
- Claim 8: buffer comprises sodium citrate
Scope effect
- Claim 6 expands coverage to numerous buffers, which reduces design-around options that depend on swapping buffer chemistry.
- Sodium acetate and sodium citrate are specifically called out, indicating they likely appear in example embodiments and are likely core commercial formulations.
Antioxidant exclusion and excipient permissiveness
- Claim 2: composition is substantially free of any additional antioxidant
- Claim 3: composition further comprises at least one member of:
- salt, EDTA, sorbitol, a sugar, and a flavoring agent
Scope effect
- Claim 2 is a potential design-around lever (remove antioxidants). But since claim 2 says “substantially free,” the term can stay broad depending on how “substantial” is interpreted in practice and on prosecution history.
- Claim 3 prevents narrow construction arguments that would exclude common nasal excipients. It also provides a pathway for combination formulations with chelators (EDTA), sugars, and flavors without losing coverage.
Method claims track treatment indication and patient type
- Claim 10: treating a patient via intranasal administration of an effective amount of claim 1 composition
- Claim 11-12: disorder treatable with metoclopramide selected from:
- gastroparesis, emesis, delayed emesis, nausea
- Claim 13: patient is human
Scope effect
- These are standard use claims that extend enforcement to commercial sale/use conduct, but they depend on proving the formulation falls within claim 1.
Device delivery is tied to “pre-defined dose to a nostril”
- Claim 14: composition contained in a nasal administration device
- Claim 15: device adapted to deliver a pre-defined dose to a nostril
Scope effect
- This gives claim holders leverage against products that package the formulation in a compatible delivery system. It also blocks design-around attempts that use a different device form factor unless the competitor can avoid the “pre-defined dose to a nostril” feature.
What does the claim structure imply for claim construction and litigation posture?
A. Claim 1 is the infringement anchor
Almost every downstream claim depends on claim 1 being met. Claim 1 thus controls:
- the pH constraint
- preservative selection and concentration bounds
- the accelerated stability threshold definition
B. The stability metric is likely to dominate validity and non-infringement
The stability limitation:
- < about 2% average change in percent O.D. per week per 200 mg/mL metoclopramide
is both a technical requirement and a potential evidentiary pivot.
- If a competitor makes the same composition but uses a different measuring method, the dispute shifts to whether their method maps to the claimed metric and whether their stability results meet the numeric limit.
- If a competitor avoids the stability metric by reformulation (different excipients, different preservative blend, different viscosity profile affecting droplet/film properties), they can create a factual non-infringement posture even if pH and preservative overlap.
C. “Substantially free” antioxidant language creates a fuzzier boundary
Claim 2 likely invites interpretation and testing-based argument. Still, it is a negative limitation that can be managed through formulation documentation and ingredient listings.
How can a competitor design around while staying inside metoclopramide intranasal delivery?
Using only the claim boundaries provided, a competitor’s highest-probability design levers are:
- pH: avoid pH > about 4.5
- Preservative selection: avoid BAC in the ≥0.025% to 0.05% band and avoid benzyl alcohol in the <1% framework by using either:
- a different preservative system not covered by claim language, or
- a different concentration outside the claimed bands
- Stability performance: keep formulation “close” but intentionally exceed the <2% O.D. change per week threshold (or ensure their own stability assay does not support that limitation)
- Excipient set: include antioxidants outside what “substantially free” could tolerate
- Device: avoid “pre-defined dose to a nostril” configuration, if feasible with a different delivery paradigm
- Formulation concentration / tonicity: target outside metoclopramide 20.0% to 30.0% and/or osmolality 500 to 1400 mOsm/kg to reduce dependent-claim alignment
What is the likely patent landscape shape (practical map of who is exposed)?
1. Direct product risk
Companies developing metoclopramide nasal sprays/drops that:
- use pH > 4.5
- use BAC between about 0.025% and 0.05% or benzyl alcohol <1%
- can meet the claimed accelerated stability threshold
are exposed to direct product infringement of claim 1, with added leverage via dependent claims for:
- BAC subranges (claims 16-18)
- benzyl alcohol ranges (claims 9, 19-20)
- metoclopramide concentration and osmolality (claims 4-5)
- buffer types including sodium acetate/citrate (claims 6-8)
- antioxidant position (claim 2)
- device dose delivery (claims 14-15)
2. Indication and label risk
Even if a formulation argument is narrow, use claims increase exposure where commercialization aligns with:
- gastroparesis
- emesis/delayed emesis
- nausea
for human patients via intranasal administration of the claimed formulation (claims 10-13).
3. “Similar formulation but different preservative” risk
If a competitor uses intranasal metoclopramide with a different preservative (not BAC and not benzyl alcohol) or uses BAC below 0.025%, they are less likely to land within claim 1 based on the literal language.
However, because claim 1 is “comprising” (not “consisting”), excipient presence does not automatically avoid infringement; the preservative selection and concentration and the stability metric remain decisive.
Portfolio-level inference: where strength is concentrated
Given claim detail depth, the patent’s protection concentration likely runs along three axes:
-
Stability-qualified formulation space
The O.D. change requirement suggests a demonstrated degradation control effect tied to preservative choice and pH.
-
Preservative window control
BAC and benzyl alcohol bands are defined in multiple nested dependent claims.
-
Delivery and buffer robustness
Many buffer systems are covered, with explicit callouts to sodium acetate and sodium citrate, indicating expected commercial viability.
Key Takeaways
- Claim 1 is the enforceable core and requires a specific metoclopramide intranasal composition with pH > 4.5, BAC (0.025% to ~0.05%) or benzyl alcohol (<1%), and a quantified accelerated stability metric (< ~2% average O.D. change per week per 200 mg/mL after ≥4 weeks at 40°C/75% RH).
- Dependent claims tighten exposure around BAC subranges (0.025% to 0.03% and 0.025%), benzyl alcohol (up to 0.8%; 0.01% to 0.1%; ~0.75%), metoclopramide concentration (20% to 30% w/v), osmolality (500 to 1400 mOsm/kg), and buffer selection including sodium acetate and sodium citrate.
- Method claims expand risk to intranasal treatment of metoclopramide-manageable disorders including gastroparesis, emesis, delayed emesis, and nausea in humans.
- The practical design-around targets are pH, preservative selection/concentration, and the stability performance metric, with secondary levers in antioxidant inclusion and delivery-device dose architecture.
FAQs
1) Which claim should be treated as the primary infringement target?
Claim 1, because nearly all other claims depend on it through the formulation definition and the method/device elements.
2) Does the patent cover both benzalkonium chloride and benzyl alcohol?
Yes. Claim 1 defines a preservative alternative: BAC at ≥0.025% up to ~0.05% (w/v) OR benzyl alcohol at <1% (w/v).
3) What is the most technically distinguishing element of the claim?
The stability requirement under 40°C and 75% RH for at least ~4 weeks, defined by O.D. change normalized to 200 mg/mL metoclopramide and expressed as <~2% per week.
4) What indications are covered by the method claims?
Disorders treatable with metoclopramide including gastroparesis, emesis, delayed emesis, and nausea.
5) Can an antioxidant-free formulation still fall within the patent?
Yes. Claim 2 says “substantially free of any additional antioxidant,” which is compatible with an antioxidant-lean formulation while still requiring compliance with the core claim 1 stability and preservative parameters.
References (APA)
[1] U.S. Patent No. 11,813,231. Claims provided in the prompt (metoclopramide intranasal composition; pH >4.5; BAC or benzyl alcohol; accelerated stability O.D. metric; dependent narrowing of buffers, concentrations, osmolality, and device/method use).
